Biogen Swings To A $20.6 Million Quarterly Loss On A $283.8 Million RayThera Charge

The 10-Q also discloses a Swiss tax-law change and an $84.5 million fee to exit a Texas lease.

Share
Biogen Swings To A $20.6 Million Quarterly Loss On A $283.8 Million RayThera Charge

Biogen, the biopharmaceutical company behind multiple sclerosis and spinal muscular atrophy drugs, posted a third-quarter net loss of $20.6 million, or $0.14 a share, after booking $283.8 million of acquired research expense, mostly for its RayThera purchase. The quarterly report filed Wednesday also shows a Swiss tax-law change and a Texas lease buyout.

The RayThera charge

Biogen completed the RayThera acquisition on August 6 with a $225.0 million upfront cash payment, expensed immediately because the deal was treated as an asset purchase. Milestones could add $275.0 million (development) and $500.0 million (regulatory).

Revenue still grew. Total revenue was $2,804.1 million against $2,534.7 million a year earlier, and the earnings release put adjusted diluted earnings at $2.62 a share. The company raised the low end of its full-year adjusted earnings guidance to a range of $12.20 to $13.00, from $12.00 to $13.00.

A tax rate of negative 128.5%

Biogen booked $11.6 million of tax expense on a $9.0 million pretax loss, an effective rate of (128.5)%. The filing attributes the swing mainly to the non-deductible RayThera charge, partly offset by a decrease in valuation allowances on Swiss loss carryforwards "following a tax law change during the quarter." The Swiss effect carries no dollar figure.

The prior quarter's 10-Q showed a 26.4% rate and no mention of the Swiss change.

Paying $84.5 million to leave Plano

In September, Biogen exited its Plano, Texas, Reata building lease, paying about $84.5 million plus $16.3 million of rent over 12 months.

The company wrote off $143.6 million of lease liabilities and about $53.4 million of right-of-use assets, leaving a pre-tax loss of about $10.6 million. It had already booked a $52.9 million impairment on the lease in late 2025.

Milestone debts move closer

Contingent consideration liabilities total $273.9 million, of which $152.4 million is now classed short-term. The expected timing of milestone achievement moved to 2027-2028, from 2028-2030 at year-end.

The restructuring reserve stood at $66.8 million at September 30, up from $35.9 million at June 30, as severance and Apellis integration costs continue. Biogen closed the Apellis acquisition in May, adding two eye and kidney drugs.

Biogen expects top-line data from its two late-stage litifilimab lupus trials in the first half of December 2026.

Sources

More on Biogen

All Biogen (BIIB) coverage →